LETTER TO THE EDITOR

Necrotizing periodontal disease: Oral manifestation of COVID-19

We read with interest the series of cases reported by Martin Carreras-Presas, Amaro Sánchez, López-Sánchez, Jané-Salas, and Somacarrera Pérez (2020). We believe that the described oral vesiculobullous manifestations were suggestive of coronavirus disease 2019 (COVID-19) co-infections, which, at present, are overlooked and poorly understood (Cox, Loman, Bogaert, & O’Grady, 2020). Increased disease severity and mortality among individuals with respiratory viral infections are often attributed to subsequent bacterial co-infections, accounting for approximately 95% of deaths during the 1918 Spanish flu pandemic (Morens, Taubenberger, & Fauci, 2008).

We predict a spontaneous rise in the prevalence of acute periodontal lesions, particularly necrotizing periodontal disease (NPD), in accordance with the increase in COVID-19 confirmed cases. The etiology of NPD lesions may be associated with bacterial co-infections occurring intra-orally in COVID-19 patients. Metagenomic analyses of those infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) frequently detect abnormally high bacterial reads of Prevotella intermedia in addition to common pathogenic genera implicated in the onset and progression of oral diseases such as Streptococci, Fusobacterium, Treponema, and Veillonella (Chakraborty, 2020). P. intermedia is considered a major etiological bacterial species for several acute periodontal lesions, which, alongside Fusobacterium and Treponema species, constitute a large proportion of the microbiota present in NPD lesions (Herrera, Retamal-Valdes, Alonso, & Feres, 2018). NPDs are more prevalent in patients with HIV (Herrera et al., 2008). In a mechanistically similar way, SARS-CoV-2 infection may predispose individuals to NPDs through bacterial co-infection propagated by P. intermedia (Patel & Sampson, 2020). We present a case of a patient attending the King’s College Hospital with NPD and suspected COVID-19:

A 35-year-old female patient without any relevant medical history attended the acute dental emergency setting reporting fever, halitosis, intense gingival pain, and bleeding. The fever presented 3 days prior to any oral symptoms. Examination revealed that she was apyrexic. She presented bilateral submandibular lymphadenopathy, and an intra-oral examination confirmed severe halitosis, generalized erythematous and edematous gingivae, and necrotic interdental papillae in both the maxillary and mandibular labial sextants. Bleeding was evident from the gingival sulcus without provocation, and there was no detectable attachment loss. A clinical diagnosis of necrotizing gingivitis was made. Although COVID-19 was suspected, it was not possible to provide testing at the time. The patient was prescribed 400mg metronidazole three times daily for 5 days and 0.12% chlorhexidine mouthwash twice daily for 10 days. Following national guidance on COVID-19, the patient was advised to return home immediately to self-isolate for 7 days. The patient was called 5 days later and described complete resolution of her oral symptoms and fever. Notably, this patient’s oral and COVID-19 suspected symptoms had resolved following the antibiotic regimen, strengthening the role of bacterial co-infections in COVID-19 severity.

There is an urgent need to study co-infections in COVID-19 patients and encourage clinicians to diagnose these conditions early, owing to their contribution to mortality and heightened disease severity in historic pandemics of respiratory viral infections. Routine intra-oral examinations for COVID-19 patients should be provided across healthcare disciplines.

KEYWORDS
bacterial co-infection, coronavirus disease 2019, COVID-19, necrotizing periodontal disease

ACKNOWLEDGEMENTS
We thank Dr Thuy Do (University of Leeds) for her suggestions and feedback.

CONFLICT OF INTEREST
None to declare.

AUTHOR CONTRIBUTION
Jay Patel: Conceptualization; Data curation; Writing-original draft; Writing-review & editing. Julian Woolley: Writing-original draft; Writing-review & editing.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
© 2020 The Authors. Oral Diseases published by John Wiley & Sons Ltd

768 | wileyonlinelibrary.com/journal/odi
Oral Diseases. 2021;27(Suppl. 3):768–769.
LETTER TO THE EDITOR

1School of Dentistry, University of Leeds, Leeds, UK
2King’s College Hospital, London, UK

Correspondence
Jay Patel, School of Dentistry, University of Leeds, Leeds LS2 9JT, UK.
Email: dn18jyp@leeds.ac.uk

ORCID
Jay Patel  https://orcid.org/0000-0002-8188-6784
Julian Woolley  https://orcid.org/0000-0001-7879-8815

REFERENCES
Chakraborty, S. (2020). Metagenome of SARS-CoV2 patients in Shenzhen with travel to Wuhan shows a wide range of species - Lautropia, Cutibacterium, Haemophilus being most abundant - and Campylobacter explaining diarrhea. OSF Preprints. Retrieved from https://osf.io/jegwq/

Cox, M. J., Loman, N., Bogaert, D., & O’Grady, J. (2020). Co-infections: Potentially lethal and unexplored in COVID-19. Lancet Microbe, 1(1), e11. https://doi.org/10.1016/S2666-5247(20)30009-4

Herrera, D., Retamal-Valdes, B., Alonso, B., & Feres, M. (2018). Acute periodontal lesions (periodontal abscesses and necrotizing periodontal diseases) and endo-periodontal lesions. Journal of Periodontology, 89(Suppl 1), S85–S102. https://doi.org/10.1111/jcpe.12941

Martin Carreras-Presas, C., Amaro Sánchez, J., López-Sánchez, A. F., Jané-Salas, E., & Somacarrera Pérez, M. L. (2020). Oral vesiculobullous lesions associated with SARS-CoV-2 infection. Oral Diseases, https://doi.org/10.1111/odi.13382

Morens, D. M., Taubenberger, J. K., & Fauci, A. S. (2008). Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: Implications for pandemic influenza preparedness. Journal of Infectious Diseases, 198(7), 962–970. https://doi.org/10.1086/591708

Patel, J., & Sampson, V. (2020). The role of oral bacteria in COVID-19. Lancet Microbe. (in press).